Peter M. Strumph
Directeur/Membre du Conseil chez Amygdala Neurosciences, Inc.
Profil
Peter M.
Strumph is the founder of Amygdala Neurosciences, Inc. He previously held positions at Codexis, Inc. as President & Chief Executive Officer, Nile Therapeutics, Inc. as Chief Executive Officer, Capricor Therapeutics, Inc. as Chief Executive Officer, Biogen MA, Inc. as Manager-Operations Planning & Development, CV Therapeutics, Inc. as Senior Vice President-Operations, and Portola Pharmaceuticals, Inc. as Vice President-Technical & Clinical Operations.
He received his undergraduate degree from the University of Pennsylvania and his MBA from The Wharton School of the University of Pennsylvania.
Postes actifs de Peter M. Strumph
| Sociétés | Poste | Début |
|---|---|---|
Amygdala Neurosciences, Inc.
 Amygdala Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Amygdala Neurosciences, Inc. is a biopharmaceutical company. The firm focuses on improving public health by developing and commercializing therapy to treat substance use disorders. Its development programs include treatment and prevention of opioid, nicotine, alcohol and cocaine use disorders. The company was founded by Lou Lange, Ivan Diamond, Peter Strumph, Brent Blackburn, and Adrienne MacMillan in 2015 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | 01/01/2016 |
Anciens postes connus de Peter M. Strumph
| Sociétés | Poste | Fin |
|---|---|---|
| CODEXIS, INC. | Directeur Général | 22/02/2012 |
| CAPRICOR THERAPEUTICS, INC. | President | 10/06/2009 |
| Nile Therapeutics, Inc. /Old/ | President | 11/10/2007 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Directeur des opérations | 01/01/2007 |
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Peter M. Strumph
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| University of Pennsylvania | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CAPRICOR THERAPEUTICS, INC. | Health Technology |
| CODEXIS, INC. | Process Industries |
| Entreprise privées | 5 |
|---|---|
| Nile Therapeutics, Inc. /Old/ | Health Technology |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Amygdala Neurosciences, Inc.
Amygdala Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Amygdala Neurosciences, Inc. is a biopharmaceutical company. The firm focuses on improving public health by developing and commercializing therapy to treat substance use disorders. Its development programs include treatment and prevention of opioid, nicotine, alcohol and cocaine use disorders. The company was founded by Lou Lange, Ivan Diamond, Peter Strumph, Brent Blackburn, and Adrienne MacMillan in 2015 and is headquartered in San Francisco, CA. | Health Technology |